Market Report

Vaccine Sales Market Report 2026-2036

The global Vaccine Sales market is projected to grow at a CAGR of 6.3% by 2036

SKU: PHA1390 Category: Code: PHA1390Pages: 355
Clear
← Back to category Contract Services

Description

Visiongain has published a new report, Vaccine Sales Market Report 2026-2036, providing a comprehensive analysis of the global vaccine sales market, including market size, growth drivers, competitive positioning, and revenue forecasts across indication, type, route of administration, age group, and distribution channel segments.

The global vaccine sales market is valued at US$76.40bn in 2026 and is forecast to reach US$141.40bn by 2036, at a CAGR of 6.3% over the forecast period.

This growth is driven by rising infectious disease prevalence, expanding government-funded immunisation programmes in low- and middle-income countries, and accelerating investment in next-generation vaccine platforms including mRNA, viral vector, and needle-free delivery technologies.

Access a Free Sample of This Report

Download a sample to explore:

  • Market forecasts and segment breakdowns
  • Competitive and company-level insights
  • Key trends shaping the market
  • Trade, policy, and supply chain analysis

Download Free Sample Report

 

Technological Innovation Driving Market Expansion

Platform-based vaccine technologies including mRNA, viral vector, and DNA approaches are expanding vaccine pipelines and supporting product development across multiple disease areas. Candidates such as mRNA-4157 (Moderna and Merck) demonstrate growing mRNA application in oncology, while ongoing work in HIV, Nipah virus, and pandemic influenza reflects continued diversification of the vaccine development landscape.

Innovation in formulation and delivery is also supporting wider adoption. Intranasal and oral vaccines simplify administration and improve patient acceptance, particularly in paediatric populations. Emerging needle-free technologies including dissolvable microarray patches are being developed to reduce logistical complexity, minimise cold-chain dependence, and support self-administration across low-resource settings.

In December 2025, CEPI committed up to US$54.3 million to support a Phase 3 trial of Moderna’s mRNA-based H5 pandemic influenza vaccine candidate (mRNA-1018), advancing the first mRNA influenza vaccine into pivotal-stage development and strengthening the commercial pipeline for next-generation vaccine platforms.

Trade, Policy & Supply Chain Dynamics

  • The vaccine sales market is increasingly shaped by U.S. trade tariff policies, public procurement frameworks, and global supply chain dynamics.
  • Vaccine supply chains rely on cross-border sourcing of pharmaceutical ingredients, vials, stoppers, packaging materials, cold-chain components, and specialised manufacturing equipment, creating exposure to import-related cost escalation.
  • U.S. tariffs on pharmaceutical inputs and biologics manufacturing equipment are increasing cost pressures across the market, affecting both producer margins and public procurement budgets for government-funded immunisation programmes.
  • Tariff exposure is uneven across the market: larger manufacturers with U.S.-based facilities are better positioned to adapt, while smaller and import-dependent suppliers face greater margin pressure and reduced competitiveness.

Commercial Impact

  • Cost and pricing pressure: Rising input and compliance costs are affecting procurement economics for government-funded programmes, particularly for low-margin paediatric vaccines and high-volume public health initiatives
  • Supply chain shifts: Companies are accelerating localisation of vaccine manufacturing, regional fill-finish capacity, and supplier diversification to reduce tariff exposure and improve supply resilience
  • Manufacturing investment: Tariff dynamics are encouraging investment in North American and regional manufacturing infrastructure and longer-term purchasing agreements with procurement partners
  • Competitive positioning: Manufacturers with diversified, regionally anchored supply networks and established government procurement relationships are better positioned to manage cost volatility

Company Intelligence

The vaccine sales market is characterised by a mix of global pharmaceutical leaders, specialist vaccine developers, and emerging-market manufacturers competing across platform capability, regulatory credentials, and government procurement relationships.

Leading companies including GSK, Pfizer, Sanofi, Moderna, and Serum Institute of India are strengthening their positions through pipeline expansion, strategic partnerships, and geographic reach across both high-income and low- and middle-income markets.

Competition is increasingly defined by:

  • Next-generation platform technology capability across mRNA, viral vector, and needle-free delivery
  • Government and multilateral procurement relationships including Gavi and PAHO supply agreements
  • Pipeline breadth across infectious disease, oncology, and pandemic preparedness
  • Manufacturing scalability and cold-chain distribution capability

This report analyses how competitive positioning is evolving across 21 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • What is the projected size of the vaccine sales market by 2036?
  • Which segments and regions will drive growth?
  • How will advances in next-generation vaccine platforms shape market evolution?
  • What is the impact of U.S. trade tariffs on manufacturing costs and procurement budgets?
  • Who are the leading companies and how will their positions evolve?

Report Scope and Data Coverage

  • Global vaccine sales market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across indication, type, route of administration, age group, and distribution channel
  • Regional and national market forecasts across five regions and 26 leading national markets
  • Competitive intelligence on 21 leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

CTA

Segmentation Framework

By Indication

  • Viral Vaccines
  • Bacterial Vaccines
  • Cancer Vaccines
  • Allergy Vaccines
  • Others

By Type

  • Subunit Vaccines
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • mRNA Vaccines
  • Viral Vector Vaccines

By Route of Administration

  • Oral
  • Parenteral
  • Nasal

By Age Group

  • Paediatric
  • Adult

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Switzerland
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • Singapore
  • South Korea
  • Malaysia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Vaccine Sales Market Report 2026-2036
Need industry data? Please contact us today.

Company Intelligence Coverage

This report includes detailed profiles of 21 leading companies, including:

  • AstraZeneca
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • CSL
  • DAIICHI SANKYO COMPANY, LIMITED
  • Emergent BioSolutions Inc.
  • GSK plc
  • INOVIO Pharmaceuticals
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax
  • Panacea Biotec
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • SINOVAC
  • SINOPHARM
  • Takeda Pharmaceutical Company Limited
  • Tanabe Pharma Corporation
  • Valneva SE

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The vaccine sales market is evolving rapidly, driven by next-generation platform technologies, expanding government immunisation programmes, and shifting trade and supply chain dynamics.
  • Organisations that understand these dynamics will be better positioned to capture procurement opportunities, manage supply chain risk, and strengthen competitive positioning.
  • Purchase the Vaccine Sales Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Access the Full Forecast and Competitive Analysis

Purchase the Vaccine Sales Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Download sample or contact us for enterprise access

 

For enterprise licensing, customised segmentation or analyst briefings, contact Visiongain directly at contactus@visiongain.com

Government Registration
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Vaccine Sales Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Focus on Vaccine Development and Launches
3.3.1.2 Advancement in Vaccine Technology
3.3.1.3 Government-funded National Immunisation Plans in LMICs
3.3.2 Market Restraining Factors
3.3.2.1 Cold-Chain Bottlenecks in Remote Regions
3.3.2.2 Concentration of Fill-finish Capacity in CDMOs
3.3.3 Market Opportunities
3.3.3.1 Growing Focus on Next-Generation Vaccines
3.3.3.2 R&D Investments to Accelerate Development of Pipeline Candidates
3.4 U.S. Tariffs: What’s the Impact on Global Vaccine Sales Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.3 Why V-Shaped Recovery?
3.4.3.1 Impact from Tariffs
3.4.3.2 Market Dynamics and Demand Recovery
3.4.3.3 Policy and Funding Support
3.4.3.4 Timeframe for Recovery
3.4.4 U-Shaped Recovery Scenario
3.4.4.1 Why U-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 L Shaped Recovery Scenario
3.4.5.1 Why L-Shaped Recovery?
3.4.5.2 Impact from Tariffs
3.4.5.3 Market Dynamics and Demand Recovery
3.4.5.4 Policy and Funding Support
3.4.5.5 Timeframe for Recovery
3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.7 Impact of U.S. and China Trade War on Vaccine Sales Market
3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 Vaccine Sales Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Vaccine Sales Market Size Estimation and Forecast by Type
4.4 Subunit Vaccines
4.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 Inactivated
4.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.5.2 Market Share by Region, 2026 & 2036 (%)
4.6 Live Attenuated
4.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.6.2 Market Share by Region, 2026 & 2036 (%)
4.7 mRNA Vaccines
4.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.7.2 Market Share by Region, 2026 & 2036 (%)
4.8 Viral Vector Vaccines
4.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
4.8.2 Market Share by Region, 2026 & 2036 (%)

5 Vaccine Sales Market Analysis by Route of Administration
5.1 Key Findings
5.2 Route of Administration Segment: Market Attractiveness Index
5.3 Vaccine Sales Market Size Estimation and Forecast by Route of Administration
5.4 Oral
5.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Parenteral
5.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Nasal
5.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
5.6.2 Market Share by Region, 2026 & 2036 (%)

6 Vaccine Sales Market Analysis by Age Group
6.1 Key Findings
6.2 Age Group Segment: Market Attractiveness Index
6.3 Vaccine Sales Market Size Estimation and Forecast by Age Group
6.4 Adult
6.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Paediatric
6.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Vaccine Sales Market Analysis by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital & Retail Pharmacies
7.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Government Suppliers
7.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Others
7.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
7.6.2 Market Share by Region, 2026 & 2036 (%)

8 Vaccine Sales Market Analysis by Indication
8.1 Key Findings
8.2 Indication Segment: Market Attractiveness Index
8.3 Vaccine Sales Market Size Estimation and Forecast by Indication
8.4 Viral Vaccines
8.4.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.4.2 Market Share by Region, 2026 & 2036 (%)
8.5 Bacterial Vaccines
8.5.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.5.2 Market Share by Region, 2026 & 2036 (%)
8.6 Cancer Vaccines
8.6.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.6.2 Market Share by Region, 2026 & 2036 (%)
8.7 Allergy Vaccines
8.7.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.7.2 Market Share by Region, 2026 & 2036 (%)
8.8 Others
8.8.1 Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
8.8.2 Market Share by Region, 2026 & 2036 (%)

9 Vaccine Sales Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America Vaccine Sales Market Analysis
10.1 Key Findings
10.2 North America Vaccine Sales Market Attractiveness Index
10.3 North America Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
10.4 North America Vaccine Sales Market Size Estimation and Forecast by Country
10.5 North America Vaccine Sales Market Size Estimation and Forecast by Type
10.6 North America Vaccine Sales Market Size Estimation and Forecast by Route of Administration
10.7 North America Vaccine Sales Market Size Estimation and Forecast by Age Group
10.8 North America Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
10.9 North America Vaccine Sales Market Size Estimation and Forecast by Indication
10.10 U.S. Vaccine Sales Market Analysis
10.11 Canada Vaccine Sales Market Analysis

11 Europe Vaccine Sales Market Analysis
11.1 Key Findings
11.2 Europe Vaccine Sales Market Attractiveness Index
11.3 Europe Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
11.4 Europe Vaccine Sales Market Size Estimation and Forecast by Country
11.5 Europe Vaccine Sales Market Size Estimation and Forecast by Type
11.6 Europe Vaccine Sales Market Size Estimation and Forecast by Route of Administration
11.7 Europe Vaccine Sales Market Size Estimation and Forecast by Age Group
11.8 Europe Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
11.9 Europe Vaccine Sales Market Size Estimation and Forecast by Indication
11.10 Germany Vaccine Sales Market Analysis
11.11 UK Vaccine Sales Market Analysis
11.12 France Vaccine Sales Market Analysis
11.13 Italy Vaccine Sales Market Analysis
11.14 Spain Vaccine Sales Market Analysis
11.15 The Netherlands Vaccine Sales Market Analysis
11.16 Switzerland Vaccine Sales Market Analysis
11.17 Rest of Europe Vaccine Sales Market Analysis

12 Asia Pacific Vaccine Sales Market Analysis
12.1 Key Findings
12.2 Asia Pacific Vaccine Sales Market Attractiveness Index
12.3 Asia Pacific Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
12.4 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Country
12.5 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Type
12.6 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Route of Administration
12.7 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Age Group
12.8 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
12.9 Asia Pacific Vaccine Sales Market Size Estimation and Forecast by Indication
12.10 Japan Vaccine Sales Market Analysis
12.11 China Vaccine Sales Market Analysis
12.12 India Vaccine Sales Market Analysis
12.13 Australia Vaccine Sales Market Analysis
12.14 South Korea Vaccine Sales Market Analysis
12.15 Singapore Vaccine Sales Market Analysis
12.16 Malaysia Vaccine Sales Market Analysis
12.17 Rest of Asia Pacific Vaccine Sales Market Analysis

13 Latin America Vaccine Sales Market Analysis
13.1 Key Findings
13.2 Latin America Vaccine Sales Market Attractiveness Index
13.3 Latin America Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
13.4 Latin America Vaccine Sales Market Size Estimation and Forecast by Country
13.5 Latin America Vaccine Sales Market Size Estimation and Forecast by Type
13.6 Latin America Vaccine Sales Market Size Estimation and Forecast by Route of Administration
13.7 Latin America Vaccine Sales Market Size Estimation and Forecast by Age Group
13.8 Latin America Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
13.9 Latin America Vaccine Sales Market Size Estimation and Forecast by Indication
13.10 Brazil Vaccine Sales Market Analysis
13.11 Mexico Vaccine Sales Market Analysis
13.12 Argentina Vaccine Sales Market Analysis
13.13 Chile Vaccine Sales Market Analysis
13.14 Rest of Latin America Vaccine Sales Market Analysis

14 MEA Vaccine Sales Market Analysis
14.1 Key Findings
14.2 MEA Vaccine Sales Market Attractiveness Index
14.3 MEA Vaccine Sales Market by Country, 2026, 2031 & 2036 (US$ Billion)
14.4 MEA Vaccine Sales Market Size Estimation and Forecast by Country
14.5 MEA Vaccine Sales Market Size Estimation and Forecast by Type
14.6 MEA Vaccine Sales Market Size Estimation and Forecast by Route of Administration
14.7 MEA Vaccine Sales Market Size Estimation and Forecast by Age Group
14.8 MEA Vaccine Sales Market Size Estimation and Forecast by Distribution Channel
14.9 MEA Vaccine Sales Market Size Estimation and Forecast by Indication
14.10 GCC Vaccine Sales Market Analysis
14.11 South Africa Vaccine Sales Market Analysis
14.12 Rest of MEA Vaccine Sales Market Analysis

15 Company Profiles
15.1 Bavarian Nordic
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.3.1 Net Revenue, 2021-2025
15.1.3.2 R&D, 2021-2025
15.1.3.3 Regional Market Shares, 2025
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Bharat Biotech
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Product Benchmarking
15.2.4 Strategic Outlook
15.3 CSL
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2021-2025
15.3.3.2 R&D, 2021-2025
15.3.3.3 Regional Market Shares, 2025
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 Emergent BioSolutions Inc.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2021-2025
15.4.3.2 R&D, 2021-2025
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 GSK plc
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2021-2025
15.5.3.2 R&D, 2021-2025
15.5.3.3 Regional Market Shares, 2025
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 INOVIO Pharmaceuticals
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Product Benchmarking
15.7 Merck & Co., Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2021-2025
15.7.3.2 R&D, 2021-2025
15.7.3.3 Regional Market Shares, 2025
15.7.4 Product Benchmarking
15.8 Tanabe Pharma Corporation
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Product Benchmarking
15.9 Moderna, Inc.
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2021-2025
15.9.3.2 R&D, 2021-2025
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 Novavax
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Product Benchmarking
15.10.4 Strategic Outlook
15.11 Panacea Biotec
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Product Benchmarking
15.12 Pfizer Inc.
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Financial Analysis
15.12.3.1 Net Revenue, 2021-2025
15.12.3.2 R&D, 2021-2025
15.12.4 Product Benchmarking
15.12.5 Strategic Outlook
15.13 Sanofi
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2021-2025
15.13.3.2 R&D, 2021-2025
15.13.3.3 Regional Market Shares, 2025
15.13.4 Product Benchmarking
15.13.5 Strategic Outlook
15.14 Serum Institute of India Pvt. Ltd.
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Product Benchmarking
15.14.4 Strategic Outlook
15.15 AstraZeneca
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Financial Analysis
15.15.3.1 Net Revenue, 2021-2025
15.15.3.2 R&D, 2021-2025
15.15.3.3 Regional Market Shares, 2025
15.15.4 Product Benchmarking
15.16 Sinopharm
15.16.1 Company Snapshot
15.16.2 Company Overview
15.16.3 Product Benchmarking
15.17 SINOVAC
15.17.1 Company Snapshot
15.17.2 Company Overview
15.17.3 Product Benchmarking
15.17.4 Strategic Outlook
15.18 Takeda Pharmaceutical Company Limited
15.18.1 Company Snapshot
15.18.2 Company Overview
15.18.3 Financial Analysis
15.18.3.1 Net Revenue, 2021-2025
15.18.3.2 R&D, 2021-2025
15.18.3.3 Regional Market Shares, 2025
15.18.4 Product Benchmarking
15.18.5 Strategic Outlook
15.19 DAIICHI SANKYO COMPANY, LIMITED
15.19.1 Company Snapshot
15.19.2 Company Overview
15.19.3 Product Benchmarking
15.20 Valneva SE
15.20.1 Company Snapshot
15.20.2 Company Overview
15.20.3 Financial Analysis
15.20.3.1 Net Revenue, 2021-2025
15.20.3.2 R&D, 2021-2025
15.20.4 Product Benchmarking
15.20.5 Strategic Outlook
15.21 BioNTech SE
15.21.1 Company Snapshot
15.21.2 Company Overview
15.21.3 Financial Analysis
15.21.3.1 Net Revenue, 2021-2025
15.21.3.2 R&D, 2021-2025
15.21.3.3 Business Segment Market Shares, 2025
15.21.4 Product Benchmarking
15.21.5 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

List of Tables
Table 1 Vaccine Sales Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 5 Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 6 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Inactivated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 Live Attenuated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 mRNA Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 12 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Nasal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 16 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Paediatric Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 19 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Government Suppliers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 21 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 23 Viral Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 Bacterial Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 Cancer Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 Allergy Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 28 Vaccine Sales Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 29 North America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 North America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 31 North America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 32 North America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 33 North America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 34 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 35 U.S. Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 36 Canada Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 37 Europe Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 38 Europe Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 39 Europe Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 40 Europe Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 41 Europe Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 42 Europe Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 43 Germany Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 44 UK Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 45 France Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 46 Italy Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 47 Spain Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 48 The Netherlands Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 49 Switzerland Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 50 Rest of Europe Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 51 Asia Pacific Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Asia Pacific Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 53 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 54 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 55 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 56 Asia Pacific Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 57 Japan Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 58 China Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 59 India Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 60 Australia Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 61 South Korea Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 62 Singapore Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 63 Malaysia Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 65 Latin America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 66 Latin America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 67 Latin America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 68 Latin America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 69 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 70 Latin America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 71 Brazil Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 72 Mexico Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 73 Argentina Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 74 Chile Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 75 Rest of Latin America Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 76 MEA Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 77 MEA Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 78 MEA Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 79 MEA Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 80 MEA Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 81 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %, CAGR %)
Table 82 GCC Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 83 South Africa Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 84 Rest of MEA Vaccine Sales Market Forecast, 2026-2036 (US$ Bn, AGR%, CAGR%)
Table 85 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Bavarian Nordic: Product Benchmarking
Table 87 Bavarian Nordic: Strategic Outlook
Table 88 Bharat Biotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Bharat Biotech: Product Benchmarking
Table 90 Bharat Biotech: Strategic Outlook
Table 91 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 CSL: Product Benchmarking
Table 93 CSL: Strategic Outlook
Table 94 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Emergent BioSolutions Inc.: Product Benchmarking
Table 96 Emergent BioSolutions Inc.: Strategic Outlook
Table 97 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 GSK plc: Product Benchmarking
Table 99 GSK plc: Strategic Outlook
Table 100 INOVIO Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 INOVIO Pharmaceuticals: Product Benchmarking
Table 102 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Merck & Co., Inc.: Product Benchmarking
Table 104 Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Tanabe Pharma Corporation: Product Benchmarking
Table 106 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Moderna, Inc.: Product Benchmarking
Table 108 Moderna, Inc.: Strategic Outlook
Table 109 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Novavax: Product Benchmarking
Table 111 Novavax: Strategic Outlook
Table 112 Panacea Biotec.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Panacea Biotec: Product Benchmarking
Table 114 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Pfizer Inc.: Product Benchmarking
Table 116 Pfizer Inc.: Strategic Outlook
Table 117 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Sanofi: Product Benchmarking
Table 119 Sanofi: Strategic Outlook
Table 120 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Serum Institute of India Pvt. Ltd.: Product Benchmarking
Table 122 Serum Institute of India Pvt. Ltd.: Strategic Outlook
Table 123 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 AstraZeneca: Product Benchmarking
Table 125 Sinopharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Sinopharm: Product Benchmarking
Table 127 SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 SINOVAC: Product Benchmarking
Table 129 SINOVAC: Strategic Outlook
Table 130 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Takeda Pharmaceutical Company Limited: Product Benchmarking
Table 132 Takeda Pharmaceutical Company Limited: Strategic Outlook
Table 133 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
Table 135 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 Valneva SE: Product Benchmarking
Table 137 Valneva SE: Strategic Outlook
Table 138 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 BioNTech SE: Product Benchmarking
Table 140 BioNTech SE: Strategic Outlook
 
List of Figures
Figure 1 Vaccine Sales Market Segmentation
Figure 2 Vaccine Sales Market by Type: Market Attractiveness Index
Figure 3 Vaccine Sales Market by Route of Administration: Market Attractiveness Index
Figure 4 Vaccine Sales Market by Age Group: Market Attractiveness Index
Figure 5 Vaccine Sales Market by Distribution Channel: Market Attractiveness Index
Figure 6 Vaccine Sales Market by Indication: Market Attractiveness Index
Figure 7 Vaccine Sales Market Attractiveness Index by Region
Figure 8 Vaccine Sales Market: Market Dynamics
Figure 9 Vaccine Sales Market: Impact Analysis
Figure 10 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 11 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 12 Vaccine Sales Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 13 Short Term & Long Term Planning
Figure 14 Impact of U.S. and China Trade War
Figure 15 Most Impacted Countries
Figure 16 Vaccine Sales Market: Porter’s Five Forces Analysis
Figure 17 Vaccine Sales Market: PEST Analysis
Figure 18 Vaccine Sales Market Attractiveness Index by Type
Figure 19 Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 20 Vaccine Sales Market Share Forecast by Type, 2026, 2031, 2036 (%)
Figure 21 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 22 Subunit Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 23 Inactivated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 24 Inactivated Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 25 Live Attenuated Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 26 Live Attenuated Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 27 mRNA Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 28 mRNA Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 29 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 30 Viral Vector Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 31 Vaccine Sales Market Attractiveness Index by Type
Figure 32 Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 33 Vaccine Sales Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
Figure 34 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 35 Oral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 36 Parenteral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 37 Parenteral Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 38 Nasal Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 39 Nasal Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 40 Vaccine Sales Market Attractiveness Index by Age Group
Figure 41 Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 42 Vaccine Sales Market Share Forecast by Age Group, 2026, 2031, 2036 (%)
Figure 43 Adult Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 44 Adult Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 45 Paediatric Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 46 Paediatric Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 47 Vaccine Sales Market Attractiveness Index by Distribution Channel
Figure 48 Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 49 Vaccine Sales Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
Figure 50 Hospital & Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 51 Hospital & Retail Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 52 Government Suppliers Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 53 Government Suppliers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 54 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 55 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 56 Vaccine Sales Market Attractiveness Index by Indication
Figure 57 Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 58 Vaccine Sales Market Share Forecast by Indication, 2026, 2031, 2036 (%)
Figure 59 Viral Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 60 Viral Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 61 Bacterial Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 62 Bacterial Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 63 Cancer Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 64 Cancer Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 65 Allergy Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 66 Allergy Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 67 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 68 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 69 Vaccine Sales Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
Figure 70 Vaccine Sales Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 71 Vaccine Sales Market by Region, 2026-2036 (US$ Mn)
Figure 72 North America Vaccine Sales Market Attractiveness Index
Figure 73 North America Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 74 North America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 75 North America Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 76 North America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 77 North America Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 78 North America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 79 North America Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 80 North America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 81 North America Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 82 North America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 83 North America Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 84 North America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 85 North America Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 86 U.S. Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 87 Canada Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 88 Europe Vaccine Sales Market Attractiveness Index
Figure 89 Europe Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 90 Europe Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 91 Europe Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 92 Europe Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 93 Europe Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 94 Europe Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 95 Europe Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 96 Europe Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 97 Europe Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 98 Europe Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 99 Europe Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 100 Europe Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 101 Europe Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 102 Germany Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 103 UK Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 104 France Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 105 Italy Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 106 Spain Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 107 The Netherlands Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 108 Switzerland Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 109 Rest of Europe Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 110 Asia Pacific Vaccine Sales Market Attractiveness Index
Figure 111 Asia Pacific Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 112 Asia Pacific Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 113 Asia Pacific Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 114 Asia Pacific Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 115 Asia Pacific Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 116 Asia Pacific Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 117 Asia Pacific Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 118 Asia Pacific Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 119 Asia Pacific Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 120 Asia Pacific Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 121 Asia Pacific Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 122 Asia Pacific Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 123 Asia Pacific Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 124 Japan Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 125 China Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 126 India Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 127 Australia Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 128 South Korea Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 129 Singapore Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 130 Malaysia Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 131 Rest of Asia Pacific Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 132 Latin America Vaccine Sales Market Attractiveness Index
Figure 133 Latin America Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 134 Latin America Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 135 Latin America Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 136 Latin America Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 137 Latin America Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 138 Latin America Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 139 Latin America Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 140 Latin America Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 141 Latin America Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 142 Latin America Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 143 Latin America Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 144 Latin America Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 145 Latin America Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 146 Brazil Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 147 Mexico Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 148 Argentina Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 149 Chile Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 150 Rest of Latin America Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 151 MEA Vaccine Sales Market Attractiveness Index
Figure 152 MEA Vaccine Sales Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 153 MEA Vaccine Sales Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 154 MEA Vaccine Sales Market Share Forecast by Country, 2026 & 2036 (%)
Figure 155 MEA Vaccine Sales Market Forecast by Type, 2026-2036 (US$ Billion, AGR %)
Figure 156 MEA Vaccine Sales Market Share Forecast by Type, 2026 & 2036 (%)
Figure 157 MEA Vaccine Sales Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
Figure 158 MEA Vaccine Sales Market Share Forecast by Route of Administration, 2026 & 2036 (%)
Figure 159 MEA Vaccine Sales Market Forecast by Age Group, 2026-2036 (US$ Billion, AGR %)
Figure 160 MEA Vaccine Sales Market Share Forecast by Age Group, 2026 & 2036 (%)
Figure 161 MEA Vaccine Sales Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
Figure 162 MEA Vaccine Sales Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
Figure 163 MEA Vaccine Sales Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 164 MEA Vaccine Sales Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 165 GCC Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 166 South Africa Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 167 Rest of MEA Vaccine Sales Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 168 Bavarian Nordic: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 169 Bavarian Nordic: R&D, 2021-2025 (US$ Million, AGR %)
Figure 170 Bavarian Nordic: Regional Market Shares, 2025
Figure 171 CSL: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 172 CSL: R&D, 2021-2025 (US$ Million, AGR %)
Figure 173 CSL: Regional Market Shares, 2025
Figure 174 Emergent BioSolutions Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 175 Emergent BioSolutions Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 176 GSK plc: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 177 GSK plc: R&D, 2021-2025 (US$ Million, AGR %)
Figure 178 GSK plc: Regional Market Shares, 2025
Figure 179 Merck & Co., Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 180 Merck & Co., Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 181 Merck & Co., Inc.: Regional Market Shares, 2025
Figure 182 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 183 Moderna, Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 184 Pfizer Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 185 Pfizer Inc.: R&D, 2021-2025 (US$ Million, AGR %)
Figure 186 Sanofi: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 187 Sanofi: R&D, 2021-2025 (US$ Million, AGR %)
Figure 188 Sanofi: Regional Market Shares, 2025
Figure 189 AstraZeneca: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 190 AstraZeneca: R&D, 2021-2025 (US$ Million, AGR %)
Figure 191 AstraZeneca: Regional Market Shares, 2025
Figure 192 Takeda Pharmaceutical Company Limited: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 193 Takeda Pharmaceutical Company Limited: R&D, 2021-2025 (US$ Million, AGR %)
Figure 194 Takeda Pharmaceutical Company Limited: Regional Market Shares, 2025
Figure 195 Valneva SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 196 Valneva SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 197 BioNTech SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
Figure 198 BioNTech SE: R&D, 2021-2025 (US$ Million, AGR %)
Figure 199 BioNTech SE: Business Segment Market Shares (%), 2025

List of Companies Profiled in the Report
AstraZeneca
Bavarian Nordic
Bharat Biotech
BioNTech SE
CSL
DAIICHI SANKYO COMPANY, LIMITED
Emergent BioSolutions Inc.
GSK plc
INOVIO Pharmaceuticals
Merck & Co., Inc.
Moderna, Inc.
Novavax
Panacea Biotec
Pfizer Inc.
Sanofi
Serum Institute of India Pvt. Ltd.
SINOVAC
SINOPHARM
Takeda Pharmaceutical Company Limited
Tanabe Pharma Corporation
Valneva SE

List of Other Companies Mentioned in the Report
Alfasigma S.p.A.
ASKA Pharmaceutical
Bilthoven Biologicals B.V.
CanSino Biologics
Dynavax Technologies Corporation
Eurofarma
Evaxion Biotech
Eveliqure Biotechnologies GmbH
ImmunityBio, Inc.
IDT Biologika
KM Biologics Co., Ltd.
Pharmaniaga Lifescience
Primrose Bio, Inc.
RAPT Therapeutics
SK bioscience
Valneva
VarmX BV
VaxThera
Vaxxas
Vicebio
Vidal Health
Walvax Biotechnology

List of Associations Mentioned in the Report
African Vaccine Manufacturing Initiative (AVMI)
Asia Pacific Vaccine Access Facility (APVAX)
Association of Immunization Managers (AIM)
Biomedical Advanced Research and Development Authority (BARDA)
Centers for Disease Control and Prevention (CDC)
Coalition for Epidemic Preparedness Innovations (CEPI)
Developing Countries Vaccine Manufacturers Network (DCVMN)
European Centre for Disease Prevention and Control (ECDC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
Gavi, the Vaccine Alliance (Gavi)
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
International Vaccine Institute (IVI)
Japan Vaccine Industry Association (JVIA)
National Foundation for Infectious Diseases (NFID)
Pan American Health Organization (PAHO)
Pharmaceutical Research and Manufacturers of America (PhRMA)
United Nations Children’s Fund (UNICEF)
Vaccine Confidence Project (VCP)
Vaccine Manufacturers Association of India (VMAI)
World Health Organization (WHO)
World Trade Organization (WTO)